Affiliation:
1. V.A. Nasonova Research Institute of Rheumatology
Abstract
Objective: to evaluate the effect of the generic drug of zoledronic acid on bone mineral density (BMD) and markers of bone metabolism in patients with osteoporosis (OP), as well as possible long-term adverse reactions (AR) 12 months after drug administration.Patients and methods. The study included 30 postmenopausal women with OP (mean age 64±8 years) who signed an informed consent of participance in clinical observation. Patients received a single dose of generic zoledronic acid (5 mg) as a 15-minute infusion. All patients additionally took calcium and vitamin D. The dynamics of BMD and bone metabolism markers, as well as the safety and tolerability of the drug, were evaluated. Fractures that might have occurred during follow-up should have been reported as ARs.Results and discussion. During treatment with generic zoledronic acid, the increase in BMD in the lumbar region was 4.9% (p<0.0001), in the femoral neck –2.7% (p<0.01), and in the femur as a whole – 3.0% (p<0.0001). Positive dynamics (increase in BMD>2%) in the spine was detected in 26 (86.7%) patients, in the proximal femur – in 20 (66.7%) patients. There was a decrease in the intensity of pain in both the thoracic (by 62%; p=0.038) and lumbar (by 29%; p=0.022) spine. Three months after the administration of the drug, a decrease in the level of bone metabolism markers was revealed: CTX – by an average of 29.7%, and P1NP – by an average of 25.5%. ARs were post-dose reactions that occurred within the first 48 hours after drug infusion. Remote ARs, fractures of peripheral bones and vertebrae were not recorded.Conclusion. The use of the generic drug of zoledronic acid has demonstrated its positive effect on BMD and markers of bone metabolism, as well as safety.
Subject
Pharmacology (medical),Immunology,Immunology and Allergy,Rheumatology
Reference17 articles.
1. Dobrovol'skaya OV, Toroptsova NV. Adherence to treatment: influence on life quality and risk of repeated fractures in women in post-menopause after osteoporotic fracture. Lechashchii vrach. 2018;(4):35-9. (In Russ.).
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10
3. 392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.
4. Viswanathan M, Reddy S, Berkman N, et al. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018 Jun 26;319(24):2532-51. doi: 10.1001/jama.2018.6537.
5. Men’shikova LV, Khramtsova NA, Ershova OB. Immediate and long-term outcomes of fractures of the proximal femur in the elderly and their medical and social consequences (according to a multicenter study). Osteoporoz i osteopatii. 2002;(1):8-11. (In Russ.).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献